Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 7/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7426195 | 0.82 | SMN1; SMN2 (0.41) | FPR2ESR1SMN1; SMN2CSNK2A2CSNK2A1 | |
| SCHEMBL1831519 | 0.78 | FPR2 (0.50) | FPR2ALDH1A1KMT2AKDM4E | |
| SCHEMBL27505442 | 0.76 | FPR2 (0.40) | FPR2ESR1SMN1; SMN2CSNK2A2CSNK2A1 | |
| SCHEMBL28173216 | 0.75 | KMT2A (0.38) | FPR2ALDH1A1KMT2A | |
| SCHEMBL26196835 | 0.74 | KDR (0.32) | FPR2ALDH1A1KMT2A | |
| SCHEMBL31252039 | 0.73 | TLR8 (0.43) | SMN1; SMN2ALDH1A1KMT2AKDM4E | |
| SCHEMBL938206 | 0.72 | ARG1 (0.53) | FPR2ESR1SMN1; SMN2CSNK2A2CSNK2A1 | |
| SCHEMBL369240 | 0.72 | ALPL (0.54) | ESR1SMN1; SMN2ALDH1A1KMT2AKDM4E | |
| SCHEMBL15501010 | 0.72 | CSNK2A2 (0.46) | FPR2ESR1SMN1; SMN2CSNK2A2CSNK2A1 | |
| SCHEMBL4288735 | 0.72 | FPR2 (0.40) | FPR2ESR1SMN1; SMN2CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | FPR2 64/4885ESR1 2000/4885SMN1; SMN2 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.